Skip to content

Oruka Therapeutics, Inc. ORKA Share-Based Payment Award Options Outstanding - Number

Share-Based Payment Award Options Outstanding - Number at other companies

Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
7.6M+9.2%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
10.6M-19.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s share-based payment award options outstanding - number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s share-based payment award options outstanding - number?
Oruka Therapeutics, Inc. (ORKA) reported share-based payment award options outstanding - number of 5.3M in Q1 2026.
How has Oruka Therapeutics, Inc.'s share-based payment award options outstanding - number changed year-over-year?
Oruka Therapeutics, Inc.'s share-based payment award options outstanding - number increased by 62.2% year-over-year, from 3.3M to 5.3M.
What does share-based payment award options outstanding - number mean?
This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.